Latham lawyers discuss how recent developments may impact FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.
The initial months of the Trump administration have been marked by a flurry of executive orders and activity by the Department of Government Efficiency (DOGE). Those efforts, along with a recent Office of Management and Budget memorandum, may lead to drastic changes at the US Food and Drug Administration (FDA).
In this episode of Connected With Latham



